Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Life Sciences Index Present Pharma Integrates 2013

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Strategically transforming Pharma business relationships.

Date/Venue
•    Pharma Integrates 2013 will be held on Tuesday 26th and Wednesday 27th November at the Riverbank Park Plaza, London. Further details available at www.lifesciencesindex.com.

Format
•    Following the success of the inaugural Pharma Integrates 2012, PI 2013 will retain the one and a half day conference format. Chairman Professor Trevor Jones CBE, Director Allergan & President of Sigma Tau Pharmaceuticals will be opening the half day series of keynotes and plenary panel discussions. The second day will include multiple tracks, with the majority of the sessions being interactive panel discussions to stimulate information exchange and organic discussion.

Theme
•    The overarching theme of Pharma Integrates is ‘Strategically transforming Pharma business relationships’,  with presentations and panel discussions addressing key industry issues from both an early and late product life cycle perspective. In 2013, we will examine how strategic relationships are evolving and increasingly becoming a source of mutual competitive advantage. Further how such collaborations are supporting innovation, productivity, differentiation and profitable growth. Topics to be addressed will include Risk Sharing, Biosimilars, Pricing, Partnering, Open Innovation and Pharma Intellectual Property.

•    Further details of Day One and Day Two Agenda available here: http://www.lifesciencesindex.com/pharma-integrates-2013-agenda

What to expect from Pharma Integrates 2013

•    Unique panel discussion format ensuring the ultimate interactive experience.

•    Blockbuster topics that straddle a complementary profile of industry stakeholders.

•    Strategically led content dedicated to senior level strategists

•    Unrivalled networking opportunities with champagne reception, luncheon and extended breaks throughout the conference timetable.

Attendee Feedback from Pharma Integrates 2012

“Relevant, good speakers, right size. Made many new contacts – thanks!” Neil Baker, Pfizer.

“Nothing similar in the EU. Panel discussion approach very successful.” Laura Walsh, 3M.

“The event attracted high level delegates and decision makers and was very informal. Good presentations, very entertaining.” Heather Brunyee, Wockhardt.

“Enjoyed the level of attendees, good mix of stakeholders- all with a passion to improve the industry. We now need to deliver!” David Tudbury, Catalent.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!